Erica Jackson - Oric Pharmaceut | 人才画像

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 63 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Figure 1 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

Christopher T. Chen,Vishesh Khanna,Shivaani Kummar,Raghad M. Abdul-Karim,David Sommerhalder,Anthony W. Tolcher, Naoto T. Ueno,Sarah Lindsey Davis,Douglas W. Orr,Erika Hamilton,Manish R. Patel, Alexander I. Spira,Shekeab Jauhari,Vaia Florou,Maureen Duff,Rongda Xu, Jian Wang,Shravani R. Barkund,Haiying Zhou,Aleksandr Pankov,Wayne Kong,Nadine S. Jahchan,Erica L. Jackson,Jessica D. Sun, Melissa R. Junttila,Pratik S. Multani, Anneleen Daemen,Edna Chow Maneval,Pamela N. Munster

crossref（2024）

Cited0Views0Bibtex

Abstract PO2-18-04: STX-478 is a Potentially Best-in-class Mutant-Selective PI3Kα Inhibitor That Demonstrates Robust Efficacy in ER+ Breast Cancer Models As Monotherapy and in Combination with Standard of Care Agents

Trang Tieu,Leonard Buckbinder, David St. Jean,Samantha Manimala,Gregory Dowdell,Michael Huff,Jacob Alltucker,Erica Jackson,Angel Guzman-Perez,Darrin Stuart

Cancer Researchno. 9_Supplement (2024): PO2-18

Cited0Views0Bibtex

Supplementary Table 1 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

crossref（2024）

Cited0Views0Bibtex

Table 2 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

crossref（2024）

Cited0Views0Bibtex

Figure 2 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

crossref（2024）

Cited0Views0Bibtex

Supplementary Table 2 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

crossref（2024）

Cited0Views0Bibtex

Figure 3 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

crossref（2024）

Cited0Views0Bibtex

Table 1 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

crossref（2024）

Cited0Views0Bibtex

Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science

Darrin D. Stuart,Angel Guzman-Perez,Natasja Brooijmans,Erica L. Jackson,Gregory V. Kryukov,Adam A. Friedman,Axel Hoos

Cancer Discoveryno. 10 (2023): 2131-2149

Cited0Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn